FLT3 Inhibitors in AML: A Closer Look at the Changing Landscape

In this interview, Dr. Richard Stone provides his expert overview on trials involving FLT3 inhibitors that may impact future treatment best practices.

Published on January 15, 2018 in Treatment in Clinical Trials

Epigenetic Modifiers in AML: A Closer Look at Enasidenib, Ivosidenib, Pracinostat, Vorinostat, Pinometostat, and LDS1 Inhibitors

In this interview, AML thought-leader Dr. Eytan Stein details recent and ongoing clinical trials studying a variety of epigenetic modifiers.

Published on November 28, 2017 in Treatment in Clinical Trials

CPX-351 and Vosaroxin: Developments in Chemotherapy for AML

In this interview, AML thought-leaders Dr. Jorge Cortes and Dr. Farhad Ravandi provide insight on recent and ongoing clinical trials studying CPX-351 and vosaroxin.

Published on September 29, 2017 in Treatment in Clinical Trials

Immunotherapy in AML: Monoclonal Antibodies

In this interview, Dr. Naval Daver provides insight into clinical trials using monoclonal antibodies to achieve complete remission in patients with AML.

Published on May 26, 2017 in Treatment in Clinical Trials